Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Conditions: Bladder Mixed Adenocarcinoma; Bladder Urothelial Carcinoma In Situ; High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8 Interventions: Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Research